NYSE · Biotechnology

Nuvation Bio (NUVB)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+89.0%

$13.10 average target

$6.93+0.10 (+1.5%)Latest market snapshot · Yahoo Finance

Market cap$2.43B

Cash$661.0M

Quarterly burn$43.0M

Pipeline assets12

Short float25.2%

Latest coverage

News & Press Releases

External sources

Aug 21, 2026

Cantor Fitzgerald Initiates Nuvation Bio at OverweightMT Newswires

Aug 20, 2026

Nuvation Bio Gets FDA Fast Track Designation for Safusidenib in IDH1-Mutant Glioma TreatmentMT Newswires

Aug 20, 2026

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant GliomaPR Newswire

Continue with BioPharma ProUnlock 5 more recent stories and press releases.

Unlock Pro

Company profile

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.